CN101972239B - Medical application of 6-gingerol for preventing and curing radiation injury - Google Patents
Medical application of 6-gingerol for preventing and curing radiation injury Download PDFInfo
- Publication number
- CN101972239B CN101972239B CN2010102964287A CN201010296428A CN101972239B CN 101972239 B CN101972239 B CN 101972239B CN 2010102964287 A CN2010102964287 A CN 2010102964287A CN 201010296428 A CN201010296428 A CN 201010296428A CN 101972239 B CN101972239 B CN 101972239B
- Authority
- CN
- China
- Prior art keywords
- gingerol
- radiation
- group
- damage
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of natural medicines, in particular to application of 6-gingerol for preventing and curing radiation injury. In the invention, the research on the radiation injury resistance of the 6-gingerol through models of 60Co gamma ray radiation injury groups and 6-gingerol radiation treatment groups shows that the 6-gingerol has protection function on hematopoietic function injury caused by radiation.
Description
Technical field
The present invention relates to natural medicine field, be specifically related to the purposes of 6-gingerol in the control radiation damage.
Background technology
Along with developing rapidly of Application of Nuclear Technology, the chance that people contact with lonizing radiation is increasing, increased by the probability of radiation damage thereupon.Ionization radiation injury mainly comprises the influence to blood system hemopoietic function, immunologic function, free-radical generating and cell DNA damage at present; Show various pathological changes along with the prolongation of time of contact; If therefore can carry out pharmaceutical intervention in early days in damage; Promote the DNA damage reparation, the infringement that radiation is caused can significantly reduce.Present domestic control medicine mainly contains sulfur-bearing base class medicine, amifostine (WR2721), N-second cysteine, potassium iodide and cytokine class medicine; Be mainly used in anti-acute radiation injury; It is low that these medicines are tired by protection, or effective acting time is short, or toxic and side effects is big etc.; The estrogen effect that treatment causes like estriol, these have limited their clinical use widely.
Rhizoma Zingiberis Recens and Rhizoma Zingiberis are respectively fresh rhizome and the dry rhizome of zingiber Zingiber officinale Rosc., are conventional Chinese medicine.The clinical practice of Rhizoma Zingiberis Recens is quite extensive, and is also higher to its degree of concern abroad.In recent years, chemistry and the pharmacology to Rhizoma Zingiberis Recens and main active thereof reports than horn of plenty.(6-gingerol 6G) is one of volatile ingredient in the Rhizoma Zingiberis Recens to the 6-gingerol, and its molecular formula is: C
17H
26O
4, molecular weight 294.4 for yellowish white to white powder or crystal, is soluble in ethanol, is insoluble in water, and its chemical structural formula is following:
Bibliographical information 6-gingerol has heart tonifying, prevents and treats cardiovascular disease, antiplatelet or antithrombotic, antiinflammatory, antioxidation, preventing or arresting vomiting, relieving fainting, the biological activitys such as blood vessel and antitumor that contract relax.In recent years, 6-gingerol antioxidant activity has received to be paid close attention to more widely and uses, and growing directly from seeds to separate in the Rhizoma Zingiberis Recens like testimony of a witnesies such as Kikuzaki obtains the gingerol class and the Diphenylheptane compounds all has certain antioxidation [Kikuzaki H.; Kobayashi M.; Nakatani N.Phytochemistry, 1991,30 (11): 3647-3651.Kikuzaki H.; Nakatani N.Phytochemistry; 1996,43 (1): 273-277], but the 6-gingerol is used for prevention and the therapeutical effect of radiation damage does not see the pertinent literature report as yet.
Summary of the invention
(promptly the 6-gingerol can be used for preparing the medicine of preventing and treating radiation damage for 6-gingerol, the preventive and therapeutic effect of Antiradiation injury 6G), and its drug effect is excellent to the invention discloses the 6-gingerol.
The inventor passes through
60Co gamma-rays radiation damage group and 6-gingerol radiation therapy group model have been studied the Antiradiation injury effect of 6-gingerol; Find that the 6-gingerol has protective effect to radiation-induced hemopoietic function damage; Simultaneously itself and positive drug estriol are compared; After the radiation damage the 2nd day and the 7th day, each dosage 6-gingerol group and positive drug group PBL counting were all apparently higher than radiation damage group (p＜0.01).High dose 6-gingerol group numeration of leukocyte is higher than positive drug group (2 days p＜0.05,7 day p＜0.01), explain that the 6-gingerol has protective effect to the mice PBL damage that irradiation causes, and the protective effect of 6-gingerol is superior to estriol.Compare with the radiation damage group, each dosage treatment group of 6-gingerol and positive drug group MDA content reduce gradually, and SOD and GSH-P activity all obviously raise, and explains that the 6-gingerol can alleviate oxidational losses due to the radiation through reparation antioxidase system.And the antioxidation of 6-gingerol when high dose is superior to the positive drug estriol.Through the micronucleus test preliminary study influence of 6-gingerol to DNA damage due to the radiation, the result shows that the 6-gingerol can alleviate radiation-induced DNA damage, explains that the 6-gingerol has certain protective role to DNA damage due to the radiation.
Description of drawings
Fig. 1 is influence (* and radiation damage group comparison, p＜0.01 of 6-gingerol to radiation damage mice PBL; Compare with the positive drug group: #p＜0.05, △ p＜0.01.)
Below in conjunction with embodiment the Antiradiation injury pharmacologically active of 6-gingerol is done further elaboration.
Embodiment 1
1. mice
180 of 6～8W SPF in age level male mouse of kunming, body weight 20 ± 2g in that day alternates with night, room temperature (20～23) ℃ environment is raised, freely drinks water, takes food.
2. experiment grouping (totally 6 groups)
(1) normal control group: do not give irradiation and pharmaceutical intervention.
(2) radiation damage group: with 4Gy
60Co radiation gamma animal.
(3) positive drug group: first day estriol 50mg/kg intramuscular injection mice behind irradiation with fixed dosage.
(4) low dosage 6G radiation therapy group: first day 6G with 20mg/kg/d irritates the stomach mice behind irradiation.
(5) dosage 6G radiation therapy group in: first day 6G with 40mg/kg/d irritates the stomach mice behind irradiation.
(6) high dose 6G radiation therapy group: first day 6G with 80mg/kg/d irritates the stomach mice behind irradiation.
Above laboratory animal adopts SPF level mice, several 30 of every treated animal, totally 180.
3. radiation treatment and index detect
Put to death 15 of mices respectively at the 2nd day and the 7th day behind the irradiation for every group, take blood sample and each organs and tissues, detect following index of correlation:
(1) hemopoietic function index: PBL (WBC) counting;
(2) DNA damage index: bone marrow cell micronucleus analysis;
(3) anti-oxidation function index of correlation: SOD and GSH-PX determination of activity in serum and the liver, and MDA assay in the liver;
4. animal pharmacodynamic result and analysis
(1) the 6-gingerol has protective effect to radiation-induced hemopoietic function damage: studied the protective effect of 6-gingerol to radiation damage mice hemopoietic function, simultaneously itself and the sure estriol of antiradiation effect have been compared.The result shows (see figure 1), and after the radiation damage the 2nd day and the 7th day, each dosage 6-gingerol group and positive drug group PBL counting were all apparently higher than radiation damage group (p＜0.01).High dose 6-gingerol group numeration of leukocyte is higher than positive drug group (2 days p＜0.05,7 day p＜0.01), explain that the 6-gingerol has protective effect to the mice PBL damage that irradiation causes, and the protective effect of 6-gingerol is superior to estriol.
(2) the 6-gingerol has remarkable anti-oxidation function: the activity and lipid peroxidation product malonaldehyde (MDA) changes of contents of hepatic tissue superoxide dismutase (SOD) and glutathion peroxidase (GSH-Px) when measuring the 7th day, observe the 6-gingerol to radiation after the influence of body activities of antioxidant enzymes and lipid peroxidation product.Preliminary study result shows (table 1), after the 4Gy irradiation, compares with the normal control group, and radiation damage group hepatic tissue MDA content significantly increases, and SOD and GSH-P activity all obviously reduce, and the prompting radiation strengthens lipid peroxidation, destroys the antioxidase system.Compare with the radiation damage group, each dose groups of 6-gingerol and positive drug group MDA content reduce gradually, and SOD and GSH-P activity all obviously raise, and explains that the 6-gingerol can alleviate oxidational losses due to the radiation through reparation antioxidase system.And the antioxidation of 6-gingerol when high dose is superior to the positive drug estriol.
(3) the 6-gingerol can alleviate radiation-induced DNA damage: micronucleus test has been studied the influence of 6-gingerol to DNA damage due to the radiation during through the 7th day.The result shows that radiation damage group (4Gy) mouse femur bone marrow cell micronucleus rate (‰) is 18.36 ‰ (normal control groups 2.1 ‰), and each dose groups of 6-gingerol (20mg/kg, 40mg/kg and 80mg/kg) micronuclear rates is respectively 14.88 ‰, 7.38 ‰ and 3.87 ‰.Explain that the 6-gingerol has certain protective role to DNA damage due to the radiation.
Table 1. 6G is to the influence of SOD and GSH-PX activity and MDA content in the radiation damage mouse liver
Annotate: a: compare p＜0.05 with the radiation damage group; B: compare p＜0.01. with the radiation damage group
Claims (1)
1.6-gingerol is in preparation treatment or prevent the application in the medicine of radiation-induced hemopoietic function damage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102964287A CN101972239B (en) | 2010-09-26 | 2010-09-26 | Medical application of 6-gingerol for preventing and curing radiation injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102964287A CN101972239B (en) | 2010-09-26 | 2010-09-26 | Medical application of 6-gingerol for preventing and curing radiation injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101972239A CN101972239A (en) | 2011-02-16 |
| CN101972239B true CN101972239B (en) | 2012-02-08 |
Family
ID=43572171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102964287A Expired - Fee Related CN101972239B (en) | 2010-09-26 | 2010-09-26 | Medical application of 6-gingerol for preventing and curing radiation injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101972239B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102584683B (en) * | 2012-02-29 | 2014-12-24 | 中国人民解放军第四军医大学 | Synthesis of Tempol derivative and radiation protection effect |
| CN111733127A (en) * | 2020-05-27 | 2020-10-02 | 吉林大学 | Medicine for improving early embryonic development of animals and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1994997A (en) * | 2006-12-27 | 2007-07-11 | 中国药科大学 | Method for separating and purifying 6-gingerol |
-
2010
- 2010-09-26 CN CN2010102964287A patent/CN101972239B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1994997A (en) * | 2006-12-27 | 2007-07-11 | 中国药科大学 | Method for separating and purifying 6-gingerol |
Non-Patent Citations (2)
| Title |
|---|
| 张雪红等."姜酚的研究进展".《广西师范学院学报(自然科学版)》.2009,第26卷(第1期),第110-113页. |
| 郑辉等."辐射损伤后不同阶段细胞内外一氧化氮和总抗氧化能力变化的实验观察".《中华放射医学与防护杂志》.2007,第27卷(第6期),第546-548页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101972239A (en) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Diwanay et al. | Immunoprotection by botanical drugs in cancer chemotherapy | |
| AU2009252911C1 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
| Jayasuriya et al. | Anti‐inflammatory activity of Pleurotus ostreatus, a culinary medicinal mushroom, in Wistar rats | |
| Mikaeili et al. | Antifungal activities of Astragalus verus Olivier. against Trichophyton verrucosum on in vitro and in vivo guinea pig model of dermatophytosis | |
| CN103750339A (en) | Saussurea involucrate culture health-care food and application thereof | |
| Pawitan | Curcumin as adjuvant therapy in COVID-19: friend or foe? | |
| CN109010805A (en) | A kind of composition and its preparation process containing typeⅡ Collagen | |
| CN101972239B (en) | Medical application of 6-gingerol for preventing and curing radiation injury | |
| CN101018558A (en) | Pharmaceutical compositions from carapa guianensis | |
| CN109106716A (en) | The purposes of the combination of onocerin and fluorouracil in the preparation of antitumor drugs | |
| CN103948661B (en) | Pharmaceutical composition and its application for treating gynecological disease, prostatic disorders or anorectal disease | |
| CN102389559A (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN102631409B (en) | Health-care medicine formula with functions of enhancing immunity, alleviating physical fatigue and resisting tumor | |
| CN114470042B (en) | Composition for preventing and treating liver injury of animals as well as preparation method and application thereof | |
| Mehboudi et al. | Effect of a six week-swimming interval training with resveratrol consumption on apoptotic markers in the liver tissue of aged rat | |
| CN106072569B (en) | The special dietary seafood of patient's immunocyte balance is adjusted during a kind of chemicotherapy | |
| CN109224024A (en) | For preventing and treating the pharmaceutical composition and its application method of fresh-water fishes bacteria mixed infection | |
| Bawa et al. | Clinical Uses of Piperine: A Review | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN106540044B (en) | Pharmaceutical composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101983633B (en) | New application of polysaccharides from fructus rosae roxburghii for protection against ionizing radiation | |
| CN101912378A (en) | Medical application of 6-shogaol for preventing and curing radiation injury | |
| WO2019142042A1 (en) | Synergistic medicinal preparation for treating skin disorders like tinea versicolor | |
| CN101168047B (en) | Composition with radiation-proof, anti-oxidation and DNA-protection effects and use | |
| Du et al. | Effects of Zingiber officinale extract on antioxidation and lipid peroxidation in mice after exposure to 60Co-γ-ray |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120208 Termination date: 20140926 |
|
| EXPY | Termination of patent right or utility model |